ArticleLiver international : official journal of the International Association for the Study of the Liver2022
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- From targets to real world impact: a review of models of care for chronic HBV and HCV in Europe.The Lancet regional health. Europe · 2026Review
- Evaluation of the hepatitis c virus screening program in the Marche Region (Italy): experience from the Pesaro-Urbino health authority.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Screening Program for Asymptomatic Hepatitis C: Uptake and Detection in the Marche Region of Italy.Journal of clinical medicine · 2026Article
- Article
- Prevalence of Hepatitis C in the Emilia-Romagna Region of Italy: Population-Wide Screening.Viruses · 2025Article
- Prevalence of Hepatitis C Virus Among Hospitalized Patients in a Tertiary Hospital in Italy: The Basis for a National Screening Assessment Model?Microorganisms · 2025Article
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience.Viruses · 2023Article
- Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain.Communications medicine · 2023Article
- Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.PloS one · 2023Article
- Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe World Health Organization (WHO) goal of hepatitis C virus (HCV) elimination by 2030 relies on the scaling-up of both identification and linkage to care of the infected population, worldwide. In Italy, the estimated burden of HCV carriers who are unaware of their infection amounts to 200 000 persons, a projection that reinforces the need for broadening population access to effective screening programmes.
methodsA pivotal screening programme targeting subjects born between 1969 and 1989 has been conducted in Lombardy, Northern Italy, where point-of-care (POC) testing was offered for free concomitantly to COVID-19 vaccination.
resultsAmongst 7219 subjects born between 1969 and 1989 who underwent HCV screening through POC, 7 (0.10%) subjects tested anti-HCV positive: 5 (0.07%) had confirmed anti-HCV positivity (Table 1) and 4 of them (0.05%) were HCV-RNA positive by standard confirmation tests.
conclusionsThis pivotal study demonstrated the feasibility of a POC-based anti-HCV screening programme in young adults undergoing COVID-19 vaccination. The prevalence of HCV infection in subjects born in the 1969-1989 cohort in Italy seems to be lower than previously estimated. Whether the extension of this programme to subjects born before 1969 could lead to improved screening effectiveness should be a matter of debate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.